Safety and effectiveness of rivaroxaban in anticoagulation therapy for elderly patients with atrial fibrillation and venous thromboembolism: a prospective observational study

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPC-17012858

Enrollment

Unknown

Registered

2017-10-01

Start date

2017-10-10

Completion date

Unknown

Last updated

2017-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

thrombosis

Interventions

rivaroxaban cohort:rivaroxaban

non-rivaroxaban cohort:non-rivaroxaban

Eligibility

Sex/Gender

All

Age

75 Years to 180 Years

Inclusion criteria

Inclusion criteria: patients aged =75 years, with a diagnosis of nonvalvular AF and/or symptomatic VTE including acute symptomatic deep-vein thrombosis (DVT) and pulmonary embolism (PE).

Exclusion criteria

Exclusion criteria: participation in other clinical study

Design outcomes

Primary

Measure	Time frame
major bleeding events;	—

Secondary

Measure	Time frame
non-major bleeding events;thromboembolic events;death event;	—

Countries

China

Contacts

Public ContactShunyan Chen

Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine

zhenli1991@163.com+86 15216635171

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026